Literature DB >> 32340902

Partial-breast irradiation versus whole-breast radiotherapy for early breast cancer: A systematic review and update meta-analysis.

Gustavo Arruda Viani1, Caio Viani Arruda2, Alexandre Ciufi Faustino3, Ligia Issa De Fendi3.   

Abstract

PURPOSE: The purpose of this study was to compare the treatment outcomes of partial-breast irradiation (PBI) versus whole-breast radiotherapy (WBRT) in early breast cancer. METHODS AND MATERIALS: Eligible randomized clinical trials were identified on Medline, Embase, the Cochrane Library, and the proceedings of annual meetings through December 2019. A meta-analysis for local recurrence (LR), overall mortality (OM), and non-breast cancer mortality (NBCM) was conducted. When possible, the outcomes were calculated for 5, 7, and 10 years of followup. A subgroup analysis by PBI technique (brachytherapy [BT], external beam radiotherapy [EBRT], intraoperative radiotherapy [IORT], and mixed) was performed. A p value < 0.05 was considered significant.
RESULTS: Eleven randomized clinical trials with a total of 14,436 patients (7186 PBI vs. 7250 WBRT) were included in the meta-analysis. The odds ratio (OR) for LR in 5 y was 1.46 (95% CI 1.15-2, p = 0.024) for PBI. In the subgroup analysis, no significant difference for LR was observed between PBI and WBRT using BT (p = 0.51), EBRT (p = 0.25), or mixed techniques (p = 0.89). The only subgroup with statistical difference was IORT 3.1 (95% CI 1.2-7.6, p = 0.014). No significant difference in LR was observed with 7 and 10 years among the groups. The OM had no difference at 5, 7, and 10 years of followup for any subgroup. A nonsignificant difference was observed comparing PBI with WBRT for NBCM OR = 1.24 (95% CI 0.98-1.57, p = 0.07). The rates of cardiac death, contralateral breast cancer, and development of second tumor were not significant.
CONCLUSIONS: The LR with PBI is low and similar to WBRT in selected early breast cancer with a longer followup. The subgroup analysis detected a significant difference for LR associated with IORT and no significant difference for BT and EBRT. Our results confirm a nonsignificant difference for OM and NBCM between PBI and WBRT.
Copyright © 2020 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Meta-analysis; Partial-breast irradiation; Whole-breast radiotherapy

Mesh:

Year:  2020        PMID: 32340902     DOI: 10.1016/j.brachy.2020.03.003

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  6 in total

Review 1.  Hypofractionated breast irradiation: a multidisciplinary review of the Senonetwork study group.

Authors:  Bruno Meduri; Fiorenza De Rose; Carlo Cabula; Isabella Castellano; Lucia Da Ros; Massimo Maria Grassi; Sandra Orrù; Fabio Puglisi; Rubina Manuela Trimboli; Antonella Ciabattoni
Journal:  Med Oncol       Date:  2021-05-10       Impact factor: 3.064

2.  Radiation-induced breast angiosarcoma: report of two patients after accelerated partial breast irradiation (APBI) and review of the literature.

Authors:  Salvatore Cozzi; Masoumeh Najafi; Lilia Bardoscia; Maria Paola Ruggieri; Lucia Giaccherini; Gladys Blandino; Andrea Botti; Patrizia Ciammella; Cinzia Iotti
Journal:  Rep Pract Oncol Radiother       Date:  2021-09-30

Review 3.  Partial breast irradiation versus whole breast radiotherapy for early breast cancer.

Authors:  Brigid E Hickey; Margot Lehman
Journal:  Cochrane Database Syst Rev       Date:  2021-08-30

Review 4.  Radiodermatitis and Fibrosis in the Context of Breast Radiation Therapy: A Critical Review.

Authors:  Sofiane Allali; Youlia Kirova
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

Review 5.  Breast cancer: an up-to-date review and future perspectives.

Authors:  Ruoxi Hong; Binghe Xu
Journal:  Cancer Commun (Lond)       Date:  2022-09-08

6.  Health-related quality of life of early-stage breast cancer patients after different radiotherapy regimens.

Authors:  Daphne H M Jacobs; Ramona K Charaghvandi; Nanda Horeweg; John H Maduro; Gabrielle Speijer; Ellen M A Roeloffzen; Mirjam Mast; Enja Bantema-Joppe; Anna L Petoukhova; Desirée H J G van den Bongard; Peter Koper; Anne P G Crijns; Corrie A M Marijnen; Helena M Verkooijen
Journal:  Breast Cancer Res Treat       Date:  2021-07-03       Impact factor: 4.872

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.